Loss of hepatitis B surface antigen from the serum of patients with chronic hepatitis treated with lamivudine

Journal of Medical Virology

Volumn 79, Issue 10, 2007, Pages 1472-1477

  Kobayashi, Mariko ^a   Suzuki, Fumitaka ^a   Akuta, Norio ^a   Hosaka, Tetsuya ^a   Sezaki, Hitomi ^a   Yatsuji, Hiromi ^a   Kobayashi, Masahiro ^a   Suzuki, Yoshiyuki ^a   Arase, Yasuji ^a   Ikeda, Kenji ^a   Watahiki, Sachiyo ^a   Iwasaki, Satomi ^a   Miyakawa, Yuzo ^b   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

^b Miyakawa Memorial Research Foundation   (Japan)

Author keywords

Chronic hepatitis; Hepatitis B e antigen; Hepatitis B surface antigen; Hepatitis B virus; Lamivudine

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HAZARD RATIO; HEMAGGLUTINATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREVALENCE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; TOKYO; TREATMENT OUTCOME; VIRAL LOAD;

HEPATITIS B VIRUS;

EID: 34548216805     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20994     Document Type: Article

References (37)

1. Akuta N, Suzuki F, Suzuki Y, Sezaki H, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. 2005. Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: An 8-year follow-up study. J Med Virol 75:491-498.
2. Chan HL, Leung NW, Hui AY, Wong VW, Liew CT, Chim AM, Chan FK, Hung LC, Lee YT, Tam JS, Lam CW, Sung JJ. 2005. A randomized, controlled trial of combination therapy for chronic hepatitis B: Comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 142:240-250.
3. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D. 2006. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354:1001-1010.
4. Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, Miyano Y, Koike H, Kobayashi M, Koida I, Arase Y, Saitoh S, Murashima N, Ikeda K, Kumada H. 1998. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 27:1711-1716.
5. de Franchis R, Hadengue A, Lau G, Lavanchy D, Lok A, McIntyre N, Mele A, Paumgartner G, Pietrangelo A, Rodes J, Rosenberg W, Valla D. 2003. EASL International Consensus Conference on Hepatitis B. 13-14September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 39:S3-S25.
6. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA. 1999. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341:1256-1263.
7. Fattovich G, Giustina G, Sanchez-Tapias J, Quero C, Mas A, Olivotto PG, Solinas A, Almasio P, Hadziyannis S, Degos F, de Moura MC, Krogsgaard K, Pantalena M, Realdi G, Corrocher R, Schalm SW. 1998. Delayed clearance of serum HBsAg in compensated cirrhosis B: Relation to interferon alpha therapy and disease prognosis. Am J Gastroenterol 93:896-900.
8. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL. 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 348:800-807.
9. Honkoop P, Niesters HG, de Man RA, Osterhaus AD, Schalm SW. 1997. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol 26:1393-1395.
10. Hosaka T, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Someya T, Sezaki H, Akuta N, Tsubota A, Arase Y, Ikeda K, Kumada H. 2004. Adefovir dipivoxil for treatment of breakthrough hepatitis caused by lamivudine-resistant mutants of hepatitis B virus. Intervirology 47:362-369.
11. Kobayashi M, Arase Y, Ikeda K, Tsubota A, Suzuki Y, Saitoh S, Kobayashi M, Suzuki F, Akuta N, Someya T, Matsuda M, Sato J, Takagi K, Miyakawa Y, Kumada H. 2002. Viral genotypes and response to interferon in patients with acute prolonged hepatitis B virus infection of adulthood in Japan. J Med Virol 68:522-528.
12. Kumada H. 2003. Continued lamivudine therapy in patients with chronic hepatitis B. Intervirology 46:377-387.
13. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF. 1998. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 339:61-68.
14. Lai CL, Ratziu V, Yuen MF, Poynard T. 2003. Viral hepatitis B. Lancet 362:2089-2094.
15. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L. 2006. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354:1011-1020.
16. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N. 2005. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352:2682-2695.
17. Lee CM, Ong GY, Lu SN, Wang JH, Liao CA, Tung HD, Chen TM, Changchien CS. 2002. Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation. J Hepatol 37:669-674.
18. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. 1999. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 30:567-572.
19. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J. 2004. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351:1521-1531.
20. Lok AS, McMahon BJ. 2004. Chronic hepatitis B: Update of recommendations. Hepatology 39:857-861.
21. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, Gardner SD, Castiglia M. 2003. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125:1714-1722.
22. Magnius LO, Espmark JA. 1972. New specificities in Australia antigen positive sera distinct from the Le Bouvier determinants. J Immunol 109:1017-1021.
23. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL. 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348:808-816.
24. Matsumoto A, Tanaka E, Rokuhara A, Kiyosawa K, Kumada H, Omata M, Okita K, Hayashi N, Okanoue T, Iino S, Tanikawa K. 2005. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients. Hepatol Res 32:173-184.
25. Miyakawa Y, Mizokami M. 2003. Classifying hepatitis B virus genotypes. Intervirology 46:329-338.
26. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. 1996. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 2:1104-1108.
27. Ryu SH, Chung YH, Choi MH, Kim JA, Shin JW, Jang MK, Park NH, Lee HC, Lee YS, Suh DJ. 2003. Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: A prospective study. J Hepatol 39:614-619.
28. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, Dhillon A, Moorat A, Barber J, Gray DF. 2000. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial. Gut 46:562-568.
29. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. 2000. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 32:803-806.
30. Suzuki Y, Kumada H, Ikeda K, Chayama K, Arase Y, Saitoh S, Tsubota A, Kobayashi M, Koike M, Ogawa N, Tanikawa K. 1999. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol 30:743-748.
31. Suzuki F, Tsubota A, Akuta N, Someya T, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Miyakawa Y, Kumada H. 2002. Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy. J Gastroenterol 37:922-927.
32. Suzuki Y, Arase Y, Ikeda K, Saitoh S, Tsubota A, Suzuki F, Kobayashi M, Akuta N, Someya T, Miyakawa Y, Kumada H. 2003. Histological improvements after a three-year lamivudine therapy in patients with chronic hepatitis B in whom YMDD mutants did not or did develop. Intervirology 46:164-170.
33. Tadokoro K, Kobayashi M, Yamaguchi T, Suzuki F, Miyauchi S, Egashira T, Kumada H. 2006. Classification of hepatitis B virus genotypes by the PCR-Invader method with genotype-specific probes. J Virol Methods 138:30-39.
34. Umeda M, Marusawa H, Ueda M, Takada Y, Egawa H, Uemoto S, Chiba T. 2006. Beneficial effects of short-term lamivudine treatment for de novo hepatitis B virus reactivation after liver transplantation. Am J Transplant 6:2680-2685.
35. van Nunen AB, Hansen BE, Suh DJ, Lohr HF, Chemello L, Fontaine H, Heathcote J, Song BC, Janssen HL, de Man RA, Schalm SW. 2003. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: Relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 52:420-424.
36. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. 1993. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 119:312-323.
37. Yotsuyanagi H, Yasuda K, lino S, Moriya K, Shintani Y, Fujie H, Tsutsumi T, Kimura S, Koike K. 1998. Persistent viremia after recovery from self-limited acute hepatitis B. Hepatology 27:1377-1382.